Literature DB >> 19151271

The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis.

Nina A Guzzetta1, Faye M Evans, Eli S Rosenberg, Tom M Fazlollah, Michael J Baker, Elizabeth C Wilson, Anna M Kaiser, Steven R Tosone, Bruce E Miller.   

Abstract

BACKGROUND: Recent concern about the safety of aprotinin administration to adults has led to its suspension from worldwide markets. However, few studies have examined its safety in pediatric patients. Studies in children evaluating aprotinin's safety have been hindered by the heterogeneity of pediatric patients and the inconsistency of clinical protocols. In this investigation, we retrospectively reviewed 200 neonatal cardiac surgical cases performed at our institution to examine the safety of aprotinin, focusing on postoperative renal dysfunction, using a consistent aprotinin dosing protocol.
METHODS: Two-hundred consecutive neonates scheduled for palliative or corrective congenital cardiac surgery requiring cardiopulmonary bypass (CPB) from January 1, 2005 through February 28, 2007 were included in this retrospective investigation. Preoperative, intraoperative and postoperative data were collected and analyzed. Markers of safety included 72-h postoperative renal dysfunction, need for dialysis (peritoneal or hemodialysis), thrombosis and in-hospital mortality.
RESULTS: Neonates were divided into those who received aprotinin (aprotinin group; n = 156) and those who did not (no aprotinin group; n = 44). Twenty-four and 72-h postoperative serum creatinine levels were significantly greater than baseline levels in both groups. The degree of change in creatinine levels was highly significant and similar between the two groups. A larger percentage of neonates in the aprotinin group developed renal dysfunction, although this difference was not statistically significant. Stepwise logistic regression, assessing the impact on renal dysfunction of all variables that indicated significance between neonates who did or did not receive aprotinin and between neonates who did or did not develop renal dysfunction, identified CPB time and age as significant predictors of postoperative renal dysfunction. All neonates who developed postoperative renal dysfunction had a CPB time of more than 100 min regardless of the use of aprotinin. Additionally, using this subset, similar percentages of renal dysfunction occurred in both groups. A second multivariable regression analysis to simultaneously account for the predictors of CPB time, age and aprotinin administration found CPB time to be the only significant predictor of renal dysfunction. Incidences of postoperative dialysis, postoperative thrombosis and in-hospital mortality were not statistically significantly different between the aprotinin and the no aprotinin groups.
CONCLUSION: The occurrence of postoperative renal dysfunction in neonates was more significantly predicted by the duration of CPB than by the intraoperative administration of aprotinin. CPB times of more than 100 min appeared to be a critical marker for the development of postoperative renal dysfunction. Randomized prospective trials are needed to confirm the validity of our retrospective findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151271     DOI: 10.1213/ane.0b013e318194007a

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery.

Authors:  Eric M Graham; Andrew M Atz; Jenna Gillis; Stacia M Desantis; A Lauren Haney; Rachael L Deardorff; Walter E Uber; Scott T Reeves; Francis X McGowan; Scott M Bradley; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-11-09       Impact factor: 5.209

2.  Comparative analysis of antifibrinolytic medications in pediatric heart surgery.

Authors:  Sara K Pasquali; Jennifer S Li; Xia He; Marshall L Jacobs; Sean M O'Brien; Matthew Hall; Robert D B Jaquiss; Karl F Welke; Eric D Peterson; Samir S Shah; Jeffrey P Jacobs
Journal:  J Thorac Cardiovasc Surg       Date:  2012-01-20       Impact factor: 5.209

3.  Safety of aprotinin in congenital heart operations: results from a large multicenter database.

Authors:  Sara K Pasquali; Matthew Hall; Jennifer S Li; Eric D Peterson; James Jaggers; Andrew J Lodge; Jeffrey P Jacobs; Marshall L Jacobs; Samir S Shah
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

4.  Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery.

Authors:  Tain-Yen Hsia; Tim C McQuinn; Rupak Mukherjee; Rachael L Deardorff; Jerry E Squires; Robert E Stroud; Fred A Crawford; Scott M Bradley; Scott T Reeves; Francis G Spinale
Journal:  Ann Thorac Surg       Date:  2010-06       Impact factor: 4.330

5.  The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery.

Authors:  Chih-Yuan Lin; Jeffery H Shuhaiber; Hugo Loyola; Hua Liu; Pedro Del Nido; James A DiNardo; Frank A Pigula
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

6.  Limitations of early serum creatinine variations for the assessment of kidney injury in neonates and infants with cardiac surgery.

Authors:  Mirela Bojan; Vanessa Lopez-Lopez; Philippe Pouard; Bruno Falissard; Didier Journois
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

7.  Ultrasoft microgels displaying emergent platelet-like behaviours.

Authors:  Ashley C Brown; Sarah E Stabenfeldt; Byungwook Ahn; Riley T Hannan; Kabir S Dhada; Emily S Herman; Victoria Stefanelli; Nina Guzzetta; Alexander Alexeev; Wilbur A Lam; L Andrew Lyon; Thomas H Barker
Journal:  Nat Mater       Date:  2014-09-07       Impact factor: 43.841

8.  Structural equation modelling exploration of the key pathophysiological processes involved in cardiac surgery-related acute kidney injury in infants.

Authors:  Mirela Bojan; Maria Constanza Basto Duarte; Natalia Ermak; Vanessa Lopez-Lopez; Agnès Mogenet; Marc Froissart
Journal:  Crit Care       Date:  2016-06-05       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.